Skip to main content

Search Videos and More

Showing 37 - 48 of 69 results

Previous| 1... 3 | 4 | 5 ...6 |Next

In your lipid practice, which patients with ASCVD do you prioritize for PCSK9-mediated lowering of LDL-C? Based on ODYSSEY Outcomes, what do we know about the subgroup of post-ACS patients who benefited most from alirocumab?

In your lipid practice, which patients with ASCVD do you prioritize for PCSK9-mediated lowering of LDL-C? Based on ODYSSEY Outcomes, what do we know about the subgroup of post-ACS patients who benefited most from alirocumab?

Where did the 70 mg/dL LDL-C target goal come from? Why wasn’t it set lower in the guidelines from the outset for patients with ACS?

Where did the 70 mg/dL LDL-C target goal come from? Why wasn’t it set lower in the guidelines from the outset for patients with ACS?

To what degree have you observed statin intolerance or resistance in patients with high risk CAD? What protocol do you employ to mitigate and/or manage statin intolerance? Where does the PCSK9 inhibitor fit into your sequencing strategy?

To what degree have you observed statin intolerance or resistance in patients with high risk CAD? What protocol do you employ to mitigate and/or manage statin intolerance? Where does the PCSK9 inhibitor fit into your sequencing strategy?

What is your experience deploying PCSK9 inhibitors in the clinic, and what are the most reliable and actionable triggers for deploying this program for CV risk reduction? And predictably achieving reimbursement and payor support for this therapy?

What is your experience deploying PCSK9 inhibitors in the clinic, and what are the most reliable and actionable triggers for deploying this program for CV risk reduction? And predictably achieving reimbursement and payor support for this therapy?

Can you describe the actual clinical phenotypes—actual patients referred to you by interventional or medical cardiologists—in which PCSK9 inhibition would represent a foundational approach to reduction of residual CV risk burden?

Can you describe the actual clinical phenotypes—actual patients referred to you by interventional or medical cardiologists—in which PCSK9 inhibition would represent a foundational approach to reduction of residual CV risk burden?

In the setting of secondary prevention for patients with diabetes, the role of LDL-C has special significance. How do you view the importance for the of PCSK9 inhibitors, therefore, specifically for reducing residual CV risk in the T2D population?

In the setting of secondary prevention for patients with diabetes, the role of LDL-C has special significance. How do you view the importance for the of PCSK9 inhibitors, therefore, specifically for reducing residual CV risk in the T2D population?

As a leading authority in LDL-C-mediated CV risk reduction, can you provide us with your perspective on the evidence for PCSK9 inhibitors as a foundational approach for managing a broad spectrum of patients with high risk coronary heart disease?

As a leading authority in LDL-C-mediated CV risk reduction, can you provide us with your perspective on the evidence for PCSK9 inhibitors as a foundational approach for managing a broad spectrum of patients with high risk coronary heart disease?

From the perspective of a lipid medicine specialist, how do the results of the now-published ODYSSEY Outcomes Trial, and related trials, help you select patients for PCSK9-mediated LDL-C reduction? And what targets do you advocate?

From the perspective of a lipid medicine specialist, how do the results of the now-published ODYSSEY Outcomes Trial, and related trials, help you select patients for PCSK9-mediated LDL-C reduction? And what targets do you advocate?

From a patient-centric, clinical profile perspective, which “high risk burden” patient populations do you, as an atherosclerosis specialist, single out for PCSK9-mediated LDL-C reduction?

From a lipid medicine and atherosclerosis expert’s perspective, when you look at the ODYSSEY Outcomes and Fourier Trials, what consistent or comparative message do you take from these investigations into the safety and efficacy of PCSK9 inhibitors?

From a lipid medicine and atherosclerosis expert’s perspective, when you look at the ODYSSEY Outcomes and Fourier Trials, what consistent or comparative message do you take from these investigations into the safety and efficacy of PCSK9 inhibitors?

Now, with the publication of ODYSSEY Outcomes, which demonstrated an associated, all-cause mortality reduction benefit, how do you view the foundational role of PCSK9 inhibitors in the CV risk treatment plan for high-risk patient populations?

Now, with the publication of ODYSSEY Outcomes, which demonstrated an associated, all-cause mortality reduction benefit, how do you view the foundational role of PCSK9 inhibitors in the CV risk treatment plan for high-risk patient populations?

What change in practice, based on the all-cause mortality reduction reported in ODYSSEY Outcomes, do you believe is warranted, especially as these results might impact the LDL-C level that should be targeted and the duration of therapy?

What change in practice, based on the all-cause mortality reduction reported in ODYSSEY Outcomes, do you believe is warranted, especially as these results might impact the LDL-C level that should be targeted and the duration of therapy?

Showing 37 - 48 of 69 results

Previous| 1... 3 | 4 | 5 ...6 |Next